SCHEMBL15869822

SCHEMBL15869822

COC(=O)c1cc(-c2ccccc2C(F)(F)F)n(C)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.45
▸ KDM4E B2RXH2 3/20 0.45
▸ SMN1; SMN2 Q16637 3/20 0.45
▸ RBP4 P02753 4/20 0.44
▸ HPGD P15428 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ HSD11B1 P28845 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ KMO O15229 1/20 0.40
▸ LDHA P00338 1/20 0.40
▸ MMP2 P08253 1/20 0.40
▸ MMP13 P45452 1/20 0.40
▸ MMP14 P50281 1/20 0.40
▸ SCN9A Q15858 1/20 0.40
▸ NOTUM Q6P988 2/20 0.40
▸ TRPA1 O75762 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15869823 0.85 KMO (0.52) ALDH1A1RBP4HPGDHSD11B1KMO
SCHEMBL16804991 0.80 NPC1 (0.39) ALDH1A1KDM4ESMN1; SMN2RBP4HPGD
SCHEMBL16804987 0.79 NPC1 (0.39) ALDH1A1KDM4ESMN1; SMN2RBP4HPGD
SCHEMBL15862411 0.79 NPY5R (0.50) SMN1; SMN2HSD11B1NPC1SCN9A
SCHEMBL16804995 0.78 MAPT (0.40) ALDH1A1KDM4ESMN1; SMN2HPGDGAA
SCHEMBL4296485 0.76 GRM5 (0.55) ALDH1A1KDM4ESMN1; SMN2HPGDMMP2
SCHEMBL16804982 0.76 MMP2 (0.40) ALDH1A1KDM4ESMN1; SMN2HPGDGAA
SCHEMBL29236119 0.75 NOTUM (0.45) ALDH1A1KDM4ESMN1; SMN2RBP4HPGD
SCHEMBL16804986 0.75 HPGD (0.38) ALDH1A1KDM4ESMN1; SMN2RBP4HPGD
SCHEMBL22829330 0.74 SCN10A (0.37) ALDH1A1KDM4ESMN1; SMN2RBP4HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9078899-B2 Pyrazolyl-based carboxamides II GRUENENTHAL GMBH (DE) 2015-07-14 — — US disclosed
US-9078899-B2 Pyrazolyl-based carboxamides II GRUENENTHAL GMBH (DE) 2015-07-14 — — US disclosed
WO-2014108336-A1 PYRAZOLYL-BASED CARBOXAMIDES II AS CRAC CHANNEL INHIBITORS Grünenthal GmbH (DE) 2014-07-17 — — WO disclosed
US-20140194452-A1 Pyrazolyl-Based Carboxamides II Grünenthal GmbH (DE) 2014-07-10 — — US disclosed
US-20140194452-A1 Pyrazolyl-Based Carboxamides II Grünenthal GmbH (DE) 2014-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194452-A1 Pyrazolyl-Based Carboxamides II AADAC, VDAC2, NLRP3 ALDH1A1 2400/4885KDM4E 2196/4885SMN1; SMN2 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback